TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

On Friday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $28.81 which represents a slight increase of $0.91 or 3.26% from the prior close of $27.9. The stock ...

TD Cowen has recently initiated TG Therapeutics Inc common stock (TGTX) stock to Buy rating, as announced on October 29, 2024, according to Finviz. Earlier, on August 2, 2023, Goldman had raised the ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

Third Quarter 2024 Results Key Financial Results Revenue: US$83.9m (down 49% from ...

Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), retaining the price ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on TG Therapeutics (TGTX – Research Report), with a price ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

TG Therapeutics stock crashed Monday after missing profit expectations, though sales of its multiple sclerosis treatment beat forecasts.

During the third quarter, TG Therapeutics boosted Briumvi's market penetration, driving U.S. net revenue up by over 230% year ...

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 4.46%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Yum China shares rose 8.3% to $48.83 in the pre-market trading session. Here are some other stocks moving in pre-market ...